| Recruiting | Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma Asthma | Phase 2 | 2026-03-30 |
| Not Yet Recruiting | Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia Homozygous Familial Hypercholesterolemia | Phase 3 | 2026-03-01 |
| Recruiting | Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia Hyperlipidemia; Mixed | Phase 1 / Phase 2 | 2025-12-22 |
| Recruiting | Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease Alzheimer Disease, Alzheimer Disease, Early Onset | Phase 1 / Phase 2 | 2025-11-18 |
| Recruiting | A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (Y Homozygous Familial Hypercholesterolemia | Phase 3 | 2025-06-17 |
| Recruiting | A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus Obesity, Diabetes Mellitus, Type 2 | Phase 1 / Phase 2 | 2025-05-09 |
| Recruiting | Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis Severe Hypertriglyceridemia | Phase 3 | 2025-04-24 |
| Recruiting | Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia Hypertriglyceridemia | Phase 3 | 2025-04-09 |
| Recruiting | Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2 Spinocerebellar Ataxia Type 2 | Phase 1 | 2024-12-17 |
| Recruiting | Study of ARO-INHBE in Adults With Obesity With and Without Diabetes Mellitus Obesity | Phase 1 / Phase 2 | 2024-12-04 |
| Active Not Recruiting | Study of Plozasiran in Adults With Severe Hypertriglyceridemia Severe Hypertriglyceridemia | Phase 3 | 2024-07-23 |
| Active Not Recruiting | Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia Severe Hypertriglyceridemia | Phase 3 | 2024-07-22 |
| Active Not Recruiting | Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia Hypertriglyceridemia | Phase 3 | 2024-05-21 |
| Active Not Recruiting | Study of ARO-CFB in Adult Healthy Volunteers IgA Nephropathy | Phase 1 | 2024-04-05 |
| Recruiting | Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Myotonic Dystrophy 1 | Phase 1 / Phase 2 | 2024-03-04 |
| Recruiting | Study of ARO-DUX4 in Adult and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1 Facio-Scapulo-Humeral Dystrophy | Phase 1 / Phase 2 | 2024-02-22 |
| Withdrawn | Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS) Amyotrophic Lateral Sclerosis | Phase 1 | 2024-01-01 |
| Completed | Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis | Phase 1 / Phase 2 | 2023-01-30 |
| Completed | Study of ARO-RAGE in Healthy Subjects Asthma | Phase 1 | 2022-11-29 |
| Completed | Study of ARO-APOC3 in Adults With Dyslipidemia Dyslipidemias | Phase 2 | 2022-07-07 |
| Completed | Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease Asthma | Phase 1 / Phase 2 | 2022-06-29 |
| Terminated | Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease Asthma, Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | 2022-06-27 |
| Active Not Recruiting | Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH) Homozygous Familial Hypercholesterolemia | Phase 2 | 2022-04-22 |
| Completed | Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease C3 Glomerulopathy, IgA Nephropathy | Phase 1 / Phase 2 | 2022-02-01 |
| Active Not Recruiting | Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS) Familial Chylomicronemia | Phase 3 | 2021-12-14 |
| Completed | Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia Mixed Dyslipidemia | Phase 2 | 2021-09-28 |
| Completed | Study of ARO-ANG3 in Adults With Mixed Dyslipidemia Mixed Dyslipidemia | Phase 2 | 2021-06-28 |
| Completed | Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia Severe Hypertriglyceridemia | Phase 2 | 2021-05-31 |
| Completed | Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma | Phase 1 | 2020-08-17 |
| Terminated | Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis Cystic Fibrosis, Pulmonary | Phase 1 / Phase 2 | 2020-07-30 |
| Completed | Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NAS Non-alcoholic Steatohepatitis | Phase 1 / Phase 2 | 2020-03-03 |
| Completed | Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Diseas Alpha 1-Antitrypsin Deficiency | Phase 2 | 2019-10-31 |
| Completed | Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) Alpha 1-Antitrypsin Deficiency | Phase 2 | 2019-08-07 |
| Completed | Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicron Hypertriglyceridemia, Familial Chylomicronemia | Phase 1 | 2019-03-08 |
| Completed | Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients Dyslipidemias, Familial Hypercholesterolemia, Hypertriglyceridemia | Phase 1 | 2019-01-07 |
| Completed | Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV) Hepatitis B | Phase 1 / Phase 2 | 2018-03-27 |
| Completed | Study of ARO-AAT in Normal Adult Volunteers Alpha 1-Antitrypsin Deficiency | Phase 1 | 2018-03-12 |
| Withdrawn | Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Level Alpha-1 Antitrypsin Deficiency | Phase 2 | 2016-10-01 |
| Terminated | A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB) Hepatitis B | Phase 1 | 2016-06-01 |
| Terminated | Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatiti Hepatitis B | Phase 2 | 2016-03-01 |
| Terminated | Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) Hepatitis B, Hepatitis D | Phase 2 | 2015-12-01 |
| Terminated | A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B V Hepatitis B | Phase 2 | 2015-11-01 |
| Terminated | A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B V Hepatitis B | Phase 2 | 2015-09-01 |
| Completed | A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers Healthy | Phase 1 | 2015-09-01 |
| Terminated | Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus Chronic Hepatitis B | Phase 2 | 2015-08-01 |
| Withdrawn | Study of ARC-520 in Patient With Chronic Hepatitis B Virus Chronic Hepatitis B | Phase 2 | 2015-02-01 |
| Terminated | A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD) Alpha-1 Antitrypsin Deficiency | Phase 1 | 2015-02-01 |
| Terminated | A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Hepatitis B, Chronic | Phase 2 | 2014-03-01 |
| Completed | Safety and Tolerability Study of ARC-520 in Healthy Volunteers Healthy | Phase 1 | 2013-07-01 |
| Available | Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Familial Chylomicronemia, High Risk Severe Hypertriglyceridemia (SHTG) | — | — |